Interaction of TNFi and conventional synthetic DMARD in SARS-CoV-2 vaccine response in axial spondyloarthritis and psoriatic arthritis

World Health Organization, 2022 Strangfeld, 2021, Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry, Ann Rheum Dis, 80, 930, 10.1136/annrheumdis-2020-219498 Medeiros-Ribeiro, 2021, Immunogenicity and safety of the CoronaVac inactivated vaccine in patients with autoimmune rheumatic diseases: a phase 4 trial, Nat Med, 27, 1744, 10.1038/s41591-021-01469-5 Furer, 2021, Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population: a multicentre study, Ann Rheum Dis, 80, 1330, 10.1136/annrheumdis-2021-220647 Geisen, 2021, Immunogenicity and safety of anti-SARS-CoV-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohort, Ann Rheum Dis, 80, 1306, 10.1136/annrheumdis-2021-220272 Jara, 2021, Effectiveness of an Inactivated SARS-CoV-2 Vaccine in Chile, N Engl J Med, 385, 875, 10.1056/NEJMoa2107715 Silva CA, Medeiros-Ribeiro AC, Kupa LVK. Anti-SARS-CoV-2 immunogenicity decay and incident cases six months after Sinovac-CoronaVac inactivated vaccine in autoimmune rheumatic disease patients: phase 4 prospective trial, 23 November 2021, PREPRINT (version 1) available at research square: doi: 10.21203/rs.3.rs-1054476/v1. Aikawa, 2022, Increment of immunogenicity after third dose of a homologous inactivated SARS-CoV-2 vaccine in a large population of patients with autoimmune rheumatic diseases, Ann Rheum Dis, 81, 1036, 10.1136/annrheumdis-2021-222096 Medeiros-Ribeiro, 2022, Distinct impact of DMARD combination and monotherapy in immunogenicity of an inactivated SARS-CoV-2 vaccine in rheumatoid arthritis, Ann Rheum Dis, 81, 710, 10.1136/annrheumdis-2021-221735 Yuki EFN, Borba EF, Pasoto, SG, et al. Impact of distinct therapies on antibody response to SARS-CoV-2 vaccine in systemic lupus erythematosus. Arthritis Care Res;74:562–571. Haberman, 2021, Methotrexate hampers immunogenicity to BNT162b2 DimRNA COVID-19 vaccine in immune-mediated inflammatory disease, Ann Rheum Dis, 80, 1339, 10.1136/annrheumdis-2021-220597 Friedman, 2021, Impact of disease-modifying antirheumatic drugs on vaccine immunogenicity in patients with inflammatory rheumatic and musculoskeletal diseases, Ann Rheum Dis, 80, 1255, 10.1136/annrheumdis-2021-221244 Mahil, 2021, The effect of methotrexate and targeted immunosuppression on humoral and cellular immune responses to the COVID-19 vaccine BNT162b2: a cohort study, Lancet Rheumatol, 3, e627, 10.1016/S2665-9913(21)00212-5 França, 2012, TNF blockers show distinct patterns of immune response to the pandemic influenza A H1N1 vaccine in inflammatory arthritis patients, Rheumatology (Oxford), 51, 2091, 10.1093/rheumatology/kes202 Simader, 2022, Importance of the second SARS-CoV-2 vaccination dose for achieving serological response in patients with rheumatoid arthritis and seronegative spondyloarthritis, Ann Rheum Dis, 81, 416, 10.1136/annrheumdis-2021-221347 Kappelman, 2022, Factors affecting initial humoral immune response to SARS-CoV-2 vaccines among patients with inflammatory bowel diseases, Am J Gastroenterol, 117, 462, 10.14309/ajg.0000000000001619 Kennedy, 2021, Anti-SARS-CoV-2 antibody responses are attenuated in patients with IBD treated with infliximab, Gut, 70, 865, 10.1136/gutjnl-2021-324388 Wieske, 2022, Humoral responses after second and third SARS-CoV-2 vaccination in patients with immune-mediated inflammatory disorders on immunosuppressants: a cohort study, Lancet Rheumatol, 4, e338, 10.1016/S2665-9913(22)00034-0 Cerqueira-Silva, 2022, Influence of age on the effectiveness and duration of protection of Vaxzevria and CoronaVac vaccines: a population-based study, Lancet Reg Health Am, 6, 100154 Khoury, 2021, Neutralising antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection, Nat Med, 27, 1205, 10.1038/s41591-021-01377-8 Earle, 2021, Evidence for antibody as a protective correlate for COVID-19 vaccines, Vaccine, 39, 4423, 10.1016/j.vaccine.2021.05.063 Geisen, 2021, Immunogenicity and safety of anti-SARS-CoV-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohort, Ann Rheum Dis, 80, 1306, 10.1136/annrheumdis-2021-220272 Bugatti, 2021, Methotrexate and glucocorticoids, but not anticytokine therapy, impair the immunogenicity of a single dose of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic inflammatory arthritis, Ann Rheum Dis, 80, 1635, 10.1136/annrheumdis-2021-220862 Pasoto, 2022, Inactivated SARS-CoV-2 vaccine in primary Sjögren's syndrome: humoral response, safety, and effects on disease activity, Clin Rheumatol, 1–11 Boekel, 2021, Antibody development after COVID-19 vaccination in patients with autoimmune diseases in the Netherlands: a substudy of data from two prospective cohort studies, Lancet Rheumatol, 3, e778, 10.1016/S2665-9913(21)00222-8 Furer, 2020, 2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases, Ann Rheum Dis, 79, 39, 10.1136/annrheumdis-2019-215882 Simon, 2021, SARS-CoV-2 vaccination responses in untreated, conventionally treated and anticytokine-treated patients with immune-mediated inflammatory diseases, Ann Rheum Dis, 80, 1312, 10.1136/annrheumdis-2021-220461 Benucci, 2022, Vaccination for SARS-CoV-2 in patients with psoriatic arthritis: can therapy affect the immunological response?, Front Med (Lausanne), 9, 811829, 10.3389/fmed.2022.811829 Ghasemnejad-Berenji, 2021, Can sulfasalazine as an old drug with immunomodulatory and anti-inflammatory effects be effective in COVID-19?, J Basic Clin Physiol Pharmacol, 33, 113, 10.1515/jbcpp-2021-0349 Meiruze SF, National Health Vigilance Agency (ANVISA), Brazil. Process 25351.931900/2021-84. 2021. Aikawa, 2022, Increment of immunogenicity after third dose of a homologous inactivated SARS-CoV-2 vaccine in a large population of patients with autoimmune rheumatic diseases, Ann Rheum Dis, 81, 1036, 10.1136/annrheumdis-2021-222096 Schmiedeberg, 2022, Efficacy and tolerability of a third dose of an mRNA anti-SARS-CoV-2 vaccine in patients with rheumatoid arthritis with absent or minimal serological response to two previous doses, Lancet Rheumatol, 4, e11, 10.1016/S2665-9913(21)00328-3 Machado, 2022, Safety of vaccination against SARS-CoV-2 in people with rheumatic and musculoskeletal diseases: results from the EULAR Coronavirus Vaccine (COVAX) physician-reported registry, Ann Rheum Dis, 81, 695, 10.1136/annrheumdis-2021-221490